Cargando…

Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study

OBJECTIVE: To assess whether a faecal immunochemical test (FIT) could be used to select patients with suspected colorectal cancer (CRC) symptoms for urgent investigation. DESIGN: Multicentre, double-blinded diagnostic accuracy study in 50 National Health Service (NHS) hospitals across England betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Souza, Nigel, Georgiou Delisle, Theo, Chen, Michelle, Benton, Sally, Abulafi, Muti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108285/
https://www.ncbi.nlm.nih.gov/pubmed/33087488
http://dx.doi.org/10.1136/gutjnl-2020-321956
_version_ 1783690099940130816
author D'Souza, Nigel
Georgiou Delisle, Theo
Chen, Michelle
Benton, Sally
Abulafi, Muti
author_facet D'Souza, Nigel
Georgiou Delisle, Theo
Chen, Michelle
Benton, Sally
Abulafi, Muti
author_sort D'Souza, Nigel
collection PubMed
description OBJECTIVE: To assess whether a faecal immunochemical test (FIT) could be used to select patients with suspected colorectal cancer (CRC) symptoms for urgent investigation. DESIGN: Multicentre, double-blinded diagnostic accuracy study in 50 National Health Service (NHS) hospitals across England between October 2017 and December 2019. Patients referred to secondary care with suspected CRC symptoms meeting NHS England criteria for urgent 2 weeks wait referral and triaged to investigation with colonoscopy were invited to perform a quantitative FIT. The sensitivity of FIT for CRC, and effect of relevant variables on its diagnostic accuracy was assessed. RESULTS: 9822 patients were included in the final analysis. The prevalence of CRC at colonoscopy was 3.3%. The FIT positivity decreased from 37.2% to 19.0% and 7.6%, respectively, at cut-offs of 2, 10 and 150 µg haemoglobin/g faeces (µg/g). The positive predictive values of FIT for CRC at these cut-offs were 8.7% (95% CI, 7.8% to 9.7%), 16.1% (95% CI 14.4% to 17.8%) and 31.1% (95% CI 27.8% to 34.6%), respectively, and the negative predictive values were 99.8% (95% CI 99.7% to 99.9%), 99.6% (95% CI 99.5% to 99.7%) and 98.9% (95% CI 98.7% to 99.1%), respectively. The sensitivity of FIT for CRC decreased at the same cut-offs from 97.0% (95% CI 94.5% to 98.5%) to 90.9% (95% CI 87.2% to 93.8%) and 70.8% (95% CI 65.6% to 75.7%), respectively, while the specificity increased from 64.9% (95% CI 63.9% to 65.8%) to 83.5% (95% CI 82.8% to 84.3%) and 94.6% (95% CI 94.1% to 95.0%), respectively. The area under the receiver operating characteristic curve was 0.93 (95% CI 0.92 to 0.95). CONCLUSION: FIT sensitivity is maximised to 97.0% at the lowest cut-off (2 µg/g); a negative FIT result at this cut-off can effectively rule out CRC and a positive FIT result is better than symptoms to select patients for urgent investigations. TRIAL REGISTRATION NUMBER: ISRCTN49676259.
format Online
Article
Text
id pubmed-8108285
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-81082852021-05-24 Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study D'Souza, Nigel Georgiou Delisle, Theo Chen, Michelle Benton, Sally Abulafi, Muti Gut Bowel Cancer Screening OBJECTIVE: To assess whether a faecal immunochemical test (FIT) could be used to select patients with suspected colorectal cancer (CRC) symptoms for urgent investigation. DESIGN: Multicentre, double-blinded diagnostic accuracy study in 50 National Health Service (NHS) hospitals across England between October 2017 and December 2019. Patients referred to secondary care with suspected CRC symptoms meeting NHS England criteria for urgent 2 weeks wait referral and triaged to investigation with colonoscopy were invited to perform a quantitative FIT. The sensitivity of FIT for CRC, and effect of relevant variables on its diagnostic accuracy was assessed. RESULTS: 9822 patients were included in the final analysis. The prevalence of CRC at colonoscopy was 3.3%. The FIT positivity decreased from 37.2% to 19.0% and 7.6%, respectively, at cut-offs of 2, 10 and 150 µg haemoglobin/g faeces (µg/g). The positive predictive values of FIT for CRC at these cut-offs were 8.7% (95% CI, 7.8% to 9.7%), 16.1% (95% CI 14.4% to 17.8%) and 31.1% (95% CI 27.8% to 34.6%), respectively, and the negative predictive values were 99.8% (95% CI 99.7% to 99.9%), 99.6% (95% CI 99.5% to 99.7%) and 98.9% (95% CI 98.7% to 99.1%), respectively. The sensitivity of FIT for CRC decreased at the same cut-offs from 97.0% (95% CI 94.5% to 98.5%) to 90.9% (95% CI 87.2% to 93.8%) and 70.8% (95% CI 65.6% to 75.7%), respectively, while the specificity increased from 64.9% (95% CI 63.9% to 65.8%) to 83.5% (95% CI 82.8% to 84.3%) and 94.6% (95% CI 94.1% to 95.0%), respectively. The area under the receiver operating characteristic curve was 0.93 (95% CI 0.92 to 0.95). CONCLUSION: FIT sensitivity is maximised to 97.0% at the lowest cut-off (2 µg/g); a negative FIT result at this cut-off can effectively rule out CRC and a positive FIT result is better than symptoms to select patients for urgent investigations. TRIAL REGISTRATION NUMBER: ISRCTN49676259. BMJ Publishing Group 2021-06 2020-10-21 /pmc/articles/PMC8108285/ /pubmed/33087488 http://dx.doi.org/10.1136/gutjnl-2020-321956 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Bowel Cancer Screening
D'Souza, Nigel
Georgiou Delisle, Theo
Chen, Michelle
Benton, Sally
Abulafi, Muti
Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study
title Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study
title_full Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study
title_fullStr Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study
title_full_unstemmed Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study
title_short Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study
title_sort faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2ww pathway: a diagnostic accuracy study
topic Bowel Cancer Screening
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108285/
https://www.ncbi.nlm.nih.gov/pubmed/33087488
http://dx.doi.org/10.1136/gutjnl-2020-321956
work_keys_str_mv AT dsouzanigel faecalimmunochemicaltestissuperiortosymptomsinpredictingpathologyinpatientswithsuspectedcolorectalcancersymptomsreferredona2wwpathwayadiagnosticaccuracystudy
AT georgioudelisletheo faecalimmunochemicaltestissuperiortosymptomsinpredictingpathologyinpatientswithsuspectedcolorectalcancersymptomsreferredona2wwpathwayadiagnosticaccuracystudy
AT chenmichelle faecalimmunochemicaltestissuperiortosymptomsinpredictingpathologyinpatientswithsuspectedcolorectalcancersymptomsreferredona2wwpathwayadiagnosticaccuracystudy
AT bentonsally faecalimmunochemicaltestissuperiortosymptomsinpredictingpathologyinpatientswithsuspectedcolorectalcancersymptomsreferredona2wwpathwayadiagnosticaccuracystudy
AT abulafimuti faecalimmunochemicaltestissuperiortosymptomsinpredictingpathologyinpatientswithsuspectedcolorectalcancersymptomsreferredona2wwpathwayadiagnosticaccuracystudy
AT faecalimmunochemicaltestissuperiortosymptomsinpredictingpathologyinpatientswithsuspectedcolorectalcancersymptomsreferredona2wwpathwayadiagnosticaccuracystudy